General mechanisms of coagulation and targets of anticoagulants, Thrombosis and Haemostasis, vol.109, pp.569-579, 2013. ,
New anticoagulants for secondary haemostasis : anti IIa inhibitors, Hamostaeologie, pp.256-265, 2009. ,
L'histoire des traitements anticoagulants, La Revue de M??decine Interne, vol.25, pp.315-322, 2004. ,
DOI : 10.1016/S0248-8663(04)80002-X
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.955-62 ,
DOI : 10.1016/S0140-6736(13)62343-0
URL : https://hal.archives-ouvertes.fr/hal-00935589
Les anticoagulants en France en 2012 : Etat des lieux et surveillance, Agence National des sécurité du médicament et produits de santé, 2012. ,
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models, PLoS ONE, vol.2, issue.4, 2013. ,
DOI : 10.1371/journal.pone.0062183.s007
Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US, Annals of Pharmacotherapy, vol.19, issue.2, pp.671-85, 2013. ,
DOI : 10.1016/j.jacc.2012.03.019
Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant, Acta Otorrinolaringol Esp, vol.14, pp.1-6519 ,
Extension d'indication pour le fondaparinux, AMC pratique, p.28, 2008. ,
New fundamentals in hemostasis, Physiol Rev, vol.93, pp.327-358, 2013. ,
La coagulation sanguine : vers une vue nouvelle, Journal de Biologie Médicale, p.2012 ,
Changes in activated partial thromboplastin time and international normalised ratio after on-pump and off-pump surgical revascularization of the heart, Bosn J Basic Med Sci, vol.14, issue.2, pp.70-74, 2014. ,
Physiologie de l'hémostase, EMC ; Stomatologie, pp.22-31, 2004. ,
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients, Vascular Health and Risk Management, pp.341-352, 2013. ,
Dabigatran dans la fibrillation auriculaire : études cliniques, intérêts et limites, Journal de Pharmacie de Belgique, p.2012 ,
Direct thrombin inhibitors, British Journal of Clinical Pharmacology, vol.103, issue.1, 2011. ,
DOI : 10.1111/j.1365-2125.2011.03916.x
Rivaroxaban: A New Oral Factor Xa Inhibitor, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.376-381, 2010. ,
DOI : 10.1161/ATVBAHA.110.202978
Héparine : structure, propriétés pharmacologiques et activités, EMC ; Hématologie, pp.13-022, 2010. ,
Antivitamines K : utilisation pratique EMC ; Hématologie, 13-022-D-50, p.10, 2003. ,
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thrombosis Journal, vol.11, issue.1, 2013. ,
DOI : 10.1177/1076029612441859
The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Médica, vol.22, issue.3, pp.329-370, 2012. ,
Acquired hemophilia: a case report, Pol Arch Med Wewn, vol.118, issue.4, pp.228-261, 2008. ,
Physiologie de l'hémostase primaire et de la coagulation, Biochimie et Hématologie tome 2, 3ième édition, pp.839-848, 2013. ,
Antivitamin K Drugs in Stroke Prevention, Current Vascular Pharmacology, vol.11, issue.6, pp.817-840, 2013. ,
DOI : 10.2174/157016111106140128113404
The effects is a low INR on thromboembolic, J Cardiothorac Surg, vol.79, issue.79, p.2014 ,
Guidelines on oral anticoagulation with warfarin - fourth edition, British Journal of Haematology, vol.335, issue.Suppl. 2, 2011. ,
DOI : 10.1111/j.1365-2141.2011.08753.x
Subcutaneous small heparin doses for the prevention of thrombosis in general surgery and urology, Schweiz Med Wochenschr, vol.28105, issue.26, pp.827-862, 1975. ,
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thrombosis Journal, vol.11, issue.1, 2013. ,
DOI : 10.1177/1076029612441859
Fibrillation atriale et risque thrombo-embolique, la revue du praticien médecine générale, pp.624-629, 2012. ,
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications, Acta Anaesthesiologica Scandinavica, vol.127, issue.6, pp.651-660 ,
DOI : 10.1111/aas.12319
Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories, Clinical Chemistry, vol.59, issue.5, pp.807-821, 2013. ,
DOI : 10.1373/clinchem.2012.198788
Anticoagulation : a GP primer on the new oral anticoagulants, Focus Cardiology, vol.43, issue.5, pp.254-263, 2014. ,
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays, Thrombosis and Haemostasis, vol.105, issue.2, pp.371-379, 2011. ,
DOI : 10.1160/TH10-06-0342
Monitoring direct thrombin inhibitors with a plasma diluted thrombin time, Thrombosis and Haemostasis, vol.98, issue.1, pp.234-276, 2007. ,
DOI : 10.1160/TH06-10-0607
Dabigatran etexilate et examens de biologie médicale, Agence National des sécurité du médicament et produits de santé, 2013. ,
Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study, Annals of Pharmacotherapy, vol.142, issue.1, pp.1627-1663 ,
DOI : 10.1345/aph.1R179
Dabigatran etexilate ??? a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol.103, issue.6, pp.1116-1143, 2010. ,
DOI : 10.1160/TH09-11-0758
Rivaroxaban et tests de biologie médicale, Agence National des sécurité du médicament et produits de santé, p.2012 ,
Effects of the oral, direct factor Xa inhibitor apibaxan on routine coagulation assays and anti-Xa assays, J Thromb Haemost, p.2014 ,
Laboratory assessment of rivaroxaban: a review, Thrombosis Journal, vol.11, issue.1, 2013. ,
DOI : 10.1186/1477-9560-11-11
Assays for Measuring Rivaroxaban: Their Suitability and Limitations, Therapeutic Drug Monitoring, vol.32, issue.6, pp.673-682, 2010. ,
DOI : 10.1097/FTD.0b013e3181f2f264
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays, Thrombosis and Haemostasis, vol.111, issue.2, pp.240-248, 2014. ,
DOI : 10.1160/TH13-06-0470
Acute management of bleeding in patients on novel oral anticoagulants, European Heart Journal, vol.34, issue.7, pp.489-498, 2012. ,
DOI : 10.1093/eurheartj/ehs408
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time, British Journal of Clinical Pharmacology, vol.32, issue.Suppl. 1, p.2014 ,
DOI : 10.1111/bcp.12364
Impact of dabigatran on a large panel of routine or specific coagulation assays, Thrombosis and Haemostasis, vol.107, issue.5, pp.985-97, 2012. ,
DOI : 10.1160/TH11-11-0804
New oral anticoagulants in patients with non valvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness, Drug Des Devel Ther, pp.789-798, 2014. ,
Deux nouveaux anticoagulants disponibles en 2010???????Dabigatran Etexilate et Rivaroxaban: progr??s attendus???????probl??mes pos??s, Annales Pharmaceutiques Fran??aises, vol.68, issue.6, pp.359-69, 2010. ,
DOI : 10.1016/j.pharma.2010.08.001
Pharmacologic heterogeneity of new anticoagulants, J Mal Vasc, vol.1, issue.11, pp.10-570002, 2011. ,
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thrombosis and Haemostasis, vol.107, issue.2, pp.379-87, 2012. ,
DOI : 10.1160/TH11-06-0391
Single and multiple dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects, Clin Pharmacol, vol.5, pp.177-84, 2013. ,
Performance of Various Laboratory Assays in the Measurement of Dabigatran in Patients Receiving Therapeutic Doses: A Prospective Study Based on Peak and Trough Plasma Levels, American Journal of Clinical Pathology, vol.141, issue.2, pp.262-269, 2014. ,
DOI : 10.1309/AJCPRNUMI4PVSJ7Q
The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Medica, vol.22, issue.3, pp.329-370, 2012. ,
DOI : 10.11613/BM.2012.035
Pros and cons of new oral anticoagulants, Hematology, vol.2013, issue.1, 2013. ,
DOI : 10.1182/asheducation-2013.1.464
Tutorial in Oral antithrombotic therapy: Biology and dental implications, Medicina Oral Patolog??a Oral y Cirugia Bucal, vol.18, issue.3, pp.461-72, 2013. ,
DOI : 10.4317/medoral.19140
Implications of Dabigatran, a Direct Thrombin Inhibitor, for Oral Surgery Practice, J Can Dent Assoc, vol.79, p.74, 2013. ,
Usage des nouvelles molécules anticoagulantes dans la pratique quotidienne, Journée médicale du CHR de la Citadelle, pp.10-2012 ,
Dental management considerations for a patient taking dabigatran etexilate: a case report, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol.116, issue.3, 2013. ,
DOI : 10.1016/j.oooo.2013.05.001
Hemostatic Effect of Tranexamic Acid Mouthwash in Anticoagulant-Treated Patients Undergoing Oral Surgery, New England Journal of Medicine, vol.320, issue.13, pp.840-843, 1989. ,
DOI : 10.1056/NEJM198903303201305
Practical management of patients on apixaban: a consensus guide, Thrombosis Journal, vol.11, issue.1, pp.27-37, 2013. ,
DOI : 10.2174/138161210793563338
New oral anticoagulants, Der Anaesthesist, vol.122, issue.12, pp.1252-1257, 2009. ,
DOI : 10.1007/s00101-009-1623-z
Newer clinically available antithrombotics and their antidotes, Journal of Interventional Cardiac Electrophysiology, vol.128, issue.36, 2014. ,
DOI : 10.1007/s10840-014-9910-2
???New??? direct oral anticoagulants in the perioperative setting, Current Opinion in Anaesthesiology, vol.27, issue.4, pp.409-428 ,
DOI : 10.1097/ACO.0000000000000100
Dabigatran and rivaroxaban, new oral anticoagulants. new approaches in dentistry, J Clin Exp Dent, vol.2, issue.1, pp.1-5, 2010. ,
The role of prothrombin complex concentrates in reversal of target specific anticoagulants, Thrombosis Journal, vol.12, issue.1, 2014. ,
DOI : 10.1038/nm.3102
Guideline on the management of bleeding in patients on antithrombotic agents, British Journal of Haematology, vol.18, issue.Suppl. 2, pp.35-46 ,
DOI : 10.1111/bjh.12107
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis, Archives of Cardiovascular Disease, pp.382-393 ,
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate, Circulation, issue.14, p.1241573, 2011. ,
Gestion péri-opératoire des nouveaux anticoagulants oraux, La presse médicale, p.2014 ,
DOI : 10.1016/j.jeurea.2014.10.005
Prise en charge des complications h??morragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d???int??r??t en H??mostase P??riop??ratoire (GIHP) - mars 2013, Annales Fran??aises d'Anesth??sie et de R??animation, vol.32, issue.10, 2013. ,
DOI : 10.1016/j.annfar.2013.04.016
Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct, Ann Fr Anesth Reanim, 2011. ,
Periprocedural Anticoagulation ? Adult ? Inpatient and Ambulatory ? Clinical Practice Guideline, p.2013 ,